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Abstract
Over the previous years, comprehensive studies on antiretroviral drugs resulted in the successful introduction of highly
active antiretroviral therapy (HAART) into clinical practice for treatment of HIV/AIDS. However, there is still need for new
therapeutic approaches, since HAART cannot eradicate HIV-1 from the infected organism and, unfortunately, can be
associated with long-term toxicity and the development of drug resistance. In contrast, novel gene therapy strategies may
have the potential to reverse the infection by eradicating HIV-1. For example, expression of long terminal repeat (LTR)-
specific recombinase (Tre-recombinase) has been shown to result in chromosomal excision of proviral DNA and, in
consequence, in the eradication of HIV-1 from infected cell cultures. However, the delivery of Tre-recombinase currently
depends on the genetic manipulation of target cells, a process that is complicating such therapeutic approaches and, thus,
might be undesirable in a clinical setting. In this report we demonstrate that E.coli expressed Tre-recombinases, tagged
either with the protein transduction domain (PTD) from the HIV-1 Tat trans-activator or the translocation motif (TLM) of the
Hepatitis B virus PreS2 protein, were able to translocate efficiently into cells and showed significant recombination activity
on HIV-1 LTR sequences. Tre activity was observed using episomal and stable integrated reporter constructs in transfected
HeLa cells. Furthermore, the TLM-tagged enzyme was able to excise the full-length proviral DNA from chromosomal
integration sites of HIV-1-infected HeLa and CEM-SS cells. The presented data confirm Tre-recombinase activity on
integrated HIV-1 and provide the basis for the non-genetic transient application of engineered recombinases, which may be
a valuable component of future HIV eradication strategies.
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Introduction
Viral infectious diseases like HIV/AIDS affect millions of
people worldwide and have been a global health concern for many
years. Since the beginning of the HIV epidemic the treatment
methods have been significantly evolved, resulting in the present
highly active antiretroviral therapy (HAART), a combination of
various antiretroviral drugs [1,2]. These approaches have been
effective in controlling viral replication and extending the life-span
of infected individuals. HAART, which is targeting the viral
proteins reverse transcriptase [3–5], protease [6], integrase [7], or
virus entry [8–10] has transformed HIV-1 infection into a chronic
illness [11]. Despite the clinical benefits of HAART the prospect of
life-long anti-retroviral treatment poses significant problems such
as the occurrence of drug-related toxicities [12]. Concomitantly,
HAART has considerable impact on the daily life through strict
scheduling requirements [2]. Withdrawal of HAART and
suboptimal drug adherence frequently results in emergence of
drug-resistant viruses [13,14]. Hence, there is a pressing need for
new strategies to improve and extend current therapy options,
preferable by regimes that not only block virus replication but are
also able to eliminate HIV-1 from persistent viral reservoirs [15].
An attractive therapy approach employs a LTR-specific Tre-
recombinase, which has been demonstrated to be a promising tool
for excision of the HIV-1 provirus from infected cell cultures by
recombining LTR sequences [16,17]. To date, however, the
delivery of Tre-recombinase depends on gene therapy approaches,
in which patient cells are modified to contain advanced Tre-
expressing vector systems [18–20].
A key obstacle to the development of new antiviral agents is
their efficient and safe delivery into infected cells in vivo without
causing adverse side effects in the relevant target cells [21]. Many
different technologies have been reported to improve the cellular
uptake of therapeutic macromolecules such as proteins, nucleic
acids or peptides [22–24]. Currently the most popular and efficient
technique for achieving the intracellular access of such molecules
exploits so-called protein transduction domains (PTD) or cell
penetrating peptides (CPP) from different sources [25]. PTD/CPP
(here generally referred to as PTD) based strategies were highly
successful in the delivery of various genes and proteins [21,26,27],
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employed in preclinical models of human diseases such as cancer,
psoriasis, and stroke [31–34]. However, none of these approaches
have yet advanced into the clinic. The most studied and applied
PTD are represented by peptides derived from the basic domain of
the HIV-1 Tat trans-activator, the homeodomain of Drosophila
antennapedia (Antp) and the HSV VP22 transcription factor [35–
37]. Furthermore, a powerful novel cell permeable translocation
motif (TLM), derived from the PreS2 surface antigens of Hepatitis
B virus (HBV), has been previously reported [38]. The TLM,
which is a 12 amino-acid amphipathic a-helical peptide, mediates
the energy and receptor-independent transfer of peptides, nucleic
acids and proteins across plasma membranes. This process
apparently occurs without affecting the integrity of the cell or
interfering with intracellular signal transduction cascades [38,39].
Here we describe the PTD-mediated delivery of biologically
active Tre-recombinase into human cells. Recombination of HIV-
1 LTR-specific sequences was determined by using transient and
stably integrated HIV-1 reporter constructs. The obtained results
suggest that the direct delivery of cell permeable Tre-recombinases
(CPTR) into HIV-infected cells may be a valuable and safe
component of future antiretroviral strategies that aim at virus
eradication.
Results
Cloning, over expression and purification of Tre-
recombinases in E.coli
Five Tre-recombinase expression constructs were generated in
order to analyze the cell permeability and activity of Tre on its
HIV-1 LTR DNA substrate, a 34-bp asymmetric sequence from
the primary subtype A HIV-1 strain TZB0003 termed LoxLTR
[16,40]. As depicted in Figure 1A, the expression construct HT
represents a protein, in which an N-terminal hexa histidine tag
(His-tag) is fused to Tre, which can be cleaved off by using
thrombin protease. The HNT protein contains the canonical
nuclear localization signal (NLS) from the SV40 large T antigen
[41] inserted between the His-tag and Tre-recombinase. The
HTatNT and HTLMNT constructs were generated by inserting
either the PTD from HIV-1 Tat or the HBV preS2 TLM between
the His-tag and NLS-Tre. Finally, the HTLMIRNT construct was
generated by inserting the TLM sequence as an inverted repeat
(2TLM).
The HT, HNT, HTLMIRNT genes were inserted into the
bacterial expression plasmid backbone pET28b (Novagen), while
the HTatNT and HTLMNT constructs were ligated into the
vector pTrcC (Invitrogen) as described in the methods section. All
five fusion proteins were expressed in the E.coli Rosetta strain
(Novagen) and the respective proteins were purified using Ni-NTA
metal-ion affinity and HiLoad superdex S200 gel filtration
chromatography (GE Healthcare). While the solubility and the
yield of each protein was different in each culture, the purified
proteins displayed the expected molecular mass (,40.0–45.0 kDa)
when analyzed by SDS-PAGE (Figure 1B) and reacted with anti-
Tre polyclonal antibodies in Western blot experiments (Figure 1C).
Prior to the following cell permeability studies, it was important
to determine potential cellular toxicities of the E. coli expressed
recombinant CPTR. Hence, HeLa cells were incubated with the
purified proteins for 48 h (the entire time-span of the subsequent
experiments) and their effect on cellular metabolic activity at the
highest concentration used (1 mM) was determined by alamarBlue
(Serotec) assay. As shown in the Figure 1D, no Tre-induced
undesired effects on cellular metabolism were detected in these
experiments.
Cell permeability of recombinant Tre-recombinases
Confocal laser scanning microscopy using primary polyclonal
antibodies directed against Tre and FITC-conjugated secondary
antibodies was performed in order to determine the cellular
localization of the various recombinant Tre proteins. The
respective images show Tre-specific signals in both the cytoplasm
as well as in the nucleus for all five proteins tested (Figure 2),
suggesting that all of the recombinant Tre-recombinases were able
Figure 1. Over expression of cell permeable Tre recombinases.
(A) Schematic representation of the Tre-recombinase constructs used in
this study. (B) Coomassie stained SDS-PAGE (12%) of the E. coli
expressed and purified proteins. (C) Western blot analysis of Tre-
recombinase proteins using anti-Tre polyclonal antibodies. (D) Analysis
of potential Tre-induced cellular toxicities. HeLa cells were exposed for
48 h to 1 mM of the indicated recombinant fusion proteins. Cellular
metabolic activity was subsequently tested by alamarBlue assay. NC,
negative control experiment in which Tre protein was omitted.
Numbers over each bar indicates the p values calculated by paired t-
test.
doi:10.1371/journal.pone.0031576.g001
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NLS and PTD (i.e. HT; Figure 2, panel d–f), as well as the NLS-
Tre fusion (i.e. HNT; Figure 2, panel g–i) was apparently also able
to internalize. Interestingly, this behavior was previously observed
in case of the parental Cre recombinase protein, which has been
shown to possess an intrinsic property to transduce into
mammalian cells without the support of any PTD sequence
[42,43]. Since Tre-recombinase is a protein engineered from Cre
[16], its obviously intrinsic property of internalization can be
explained by this Cre-related property. However, the intensities of
the signals for HTatNT, HTLMNT and HTLMIRNT (Figure 2,
panel j–l, panel m–o and panel p–r, respectively) were more
prominent as compared to the proteins lacking a PTD (i.e. HT
and HNT; panel d–f and panel g–i, respectively), indicating
enhanced protein transduction efficiency. The experimental
settings for confocal microscopy were identical for all panels
shown (Figure 2). Since HTatNT contains a cell penetrating
peptide motif derived from the HIV-1 Tat trans-activator protein
(Figure 1A), the potential trans-activation capacity of HTatNT was
analyzed in a control experiment (Figure S1 and File S1)
demonstrating, that HTatNT cannot activate the HIV-1 LTR
promoter. Thus, it is highly unlikely that HTatNT treatment of
HIV-1 infected cells will activate the integrated provirus.
Analysis of Tre activity
The activities of the recombinant PTD-Tre-recombinases were
first examined in a transient reporter assay. In Figure 3A the
schematic diagram of the pSVLoxLTR reporter construct is
Figure 2. Subcellular localization of cell permeable Tre in transduced HeLa cells. Cellular uptake and localization of the indicated
recombinant fusion proteins were studied by confocal laser scanning microscopy in HeLa cells. HeLa cells were exposed for 5 h to 1 mM of the various
Tre-recombinases. Subsequently, the respective cell cultures were washed twice with PBS and PBS containing 0.5 mg per ml heparin for 5 min each.
Nuclei were stained with Draq5 (blue label), Tre-recombinases (green label) with a primary polyclonal anti-Tre and secondary Cy2-labeled antibodies.
doi:10.1371/journal.pone.0031576.g002
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resistance gene (pac), which is flanked by Tre-recombinase target
sites (LoxLTR) followed by sequences encoding b-galactosidase (b-
gal). Thus, Tre-mediated recombination of LoxLTR results in pac
excision, which can be detected by PCR using the indicated
primer binding sites (denoted P1 and P2 in Figure 3A). In fact, a
1.8 kb PCR product indicates unrecombined pSVLoxLTR
plasmid, while a 724 bp fragment is indicative for the successful
recombination of its LoxLTR sites.
HeLa cells were transiently transfected with the pSVLoxLTR
reporter construct and protein transduction was performed by
incubating the transfected cells with 1 mM of the various purified
Tre proteins for 5 h. The level of recombination was determined
48 hours post protein transduction by PCR using whole genomic
DNA. No recombination was detected in a negative control
experiment lacking Tre-recombinase (Figure 3B, upper panel lane
2). In contrast, Tre-mediated recombination could be easily
verified in a positive control experiment in which HeLa cells were
cotransfected with the p3Tre expression plasmid (Figure 3B, upper
panel lane 3). Likewise, cells treated with all CPTR resulted in the
amplification of a 724 bp fragment, demonstrating that protein
transduction is an efficient way to deliver Tre activity into cells
(Figure 3B). For transfection efficiency control, all DNA samples
were also subjected to PCR control of vector derived amp-specific
sequences (Figure 3B, lower panel). Please note, that the observed
enhanced signal in case of the positive control experiment
(Figure 3B, lower panel, lane 3) resulted from the coamplification
of the pSVloxLTR- and p3Tre-derived sequences. However, we
were unable to detect the unrecombined PCR product in the
positive control culture (Figure 3B, lane 2) as well as in HTLMNT
(Figure 3B, lane 7) treated cells, indicating high recombination
efficiency. The remaining Tre variants displayed both unrecom-
bined and recombined PCR products, (Figure 3B, upper panel
lane 4–6 and lane 8). These results were also confirmed by using a
transient Tat trans-activation assay (see Figure S2 and File S1).
Taken together, these data showed that E.coli expressed recom-
binant CPTR are taken up by HeLa cells and are able to
recombine episomal LoxLTR sequences.
The essential function of a CPTR, however, is its recombination
activity at the genomic level, which is prerequisite to the application
as a tool for the removal of proviral DNA from HIV-1 infected cells.
Hence, to determine the function of Tre-recombinases at the
chromosomal level we next employed HeLa cells in which the
pSVLoxLTR reporter construct was stably integrated into the
genome. After protein transduction of these cells, genomic DNA
was again isolated and analyzed by PCR as before. As shown and in
agreement with the previous transient experiments (Figure 3B), all
recombinases were able to recombine genomic LoxLTR sequences
to some extent (Figure 3C). Once again, we were unable to detect
the unrecombined PCR product in HTLMNT fusion protein
treated cells, which may be due to highest recombination efficiency
among all proteins tested (Figure 3C, lane 5). These data indicated
that the recombinant CPTR proteins are able to enter target cells
and can also recombine LoxLTR sequences in a genomic context.
Half-life determination of selected CPTR
During the preparation of the various recombinant CPTR we
noted that particularly the HNT and HTLMIRNT proteins were
highly labile and precipitated quickly (not shown). We therefore
wanted to investigate the half-life of the HTLMNT recombinase
and of the HTatNT protein in more detail, particularly after their
internalization into mammalian cells. CEM-SS T cells were
exposed to 1 mM of HTatNT or HTLMNT protein and cell
lysates were prepared at various time points (indicated in Figure 4A
and 4B) after protein transduction and Tre stability was analyzed
by Western blotting. The HTLMNT and HTatNT proteins were
detected over the entire time period (Figure 4A and 4B) and
degradation occurred with comparable kinetics, resulting in the
degradation of ,90% of input protein at the 48 h time point of
incubation (Figure 4C).
InteractionofCPTRand theLoxLTRtargetsiteinliving cells
Next we performed chromatin immunoprecipitation (ChIP)
assays using HIV-1 infected CEM-SS T cells to directly demon-
strate the binding of selected CPTR to their specific LoxLTR
sequence in living cells. After transduction of these cells with
Figure 3. Analysis of Tre activity in HeLa cells. (A) Schematic
diagram of the pSVLoxLTR reporter construct. The LoxLTR Tre target
sequences and the P1 and P2 PCR primer sites, used for the monitoring
of Tre-mediated recombination, are indicated. Recombination results in
the de novo detection of a 724 bp PCR product. SV40 indicates the
SV40 promoter. (B) HeLa cells were transiently transfected with
pSVLoxLTR reporter plasmid, exposed to the indicated recombinant
Tre proteins (lane 4–8) and recombination activity was monitored by
PCR. M, DNA size markers; NC, negative control reaction lacking Tre; PC,
positive control reaction in which Tre was coexpressed from the
contransfected p3Tre plasmid. (C) Stable LoxLTR HeLa cells were treated
with 1 mM of the indicated CPTR and recombination activity was
analyzed as before.
doi:10.1371/journal.pone.0031576.g003
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and formaldehyde-crosslinked protein:DNA complexes were im-
munopreciptated using Tre-specific antibodies. Bound LoxLTR
sequences were amplified by specific PCR and, for visualization,
were subjected to agarose gel electrophoresis (Figure 5). Further-
more, the PCR products were confirmed by DNA sequencing (not
shown). The respective results demonstrated that both CPTR were
clearly able to recognize and bind to chromosomally integrated
LoxLTR sequences in living cells.
Expression analysis using whole human genome
microarrays
To investigate whether treatment with CPTR may significantly
alter the cellular expression profile, we performed a transcriptome
analysis using whole human genome microarrays (see supplemen-
tary methods for details). The complete dataset has been deposited
in NCBI’s Gene Expression Omnibus (GEO) database, accession
number GSE32643 (http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE32643). As shown in Figure S3 (see also File
S1), at 48 hours post treatment only a few genes showed
differential expression levels when compared to HTLMNT
untreated CEM-SS cells. Overall, we observed 17 and 25 genes
which were more than twofold up- or downregulated, respectively
(see Tables S1 and S2). Out of these, only 8 genes showed a more
than 2.5-fold expression change, and only a single gene
(HMGCS1, see Table S2) was regulated more than threefold,
indicating that the expression profile of CPTR-treated cells does
indeed not differ substantially from the untreated control cells.
Recombination of the full-length HIV-1 proviral genome
The results obtained at this point demonstrated that CPTR
proteins were able to recognize and recombine HIV-1 LoxLTR
Figure 4. Protein stability of selected CPTR in mammalian cells. Total cellular lysates were prepared at indicated time points from (A)
HTLMNT and (B) HTatNT transduced and HIV-1 infected CEM-SS cells. Tre-recombinases were detected by Western analysis using anti-Tre polyclonal
antibodies (upper panel). Equal sample loading was verified by detection of tubulin (lower panel). (C) Relative intensity of CPTR proteins at indicated
time points.
doi:10.1371/journal.pone.0031576.g004
Figure 5. Interaction of CPTR with LoxLTR sites in living cells. (A) Schematic representation of human genomic DNA containing HIV-1
provirus with flanking LTR. The Tre recombinase binding sequences, LoxLTR, shown in black box and red arrows indicates the primers used for PCR
analysis. (B) ChIP assay of extracts derived from CPTR transduced and HIV-infected CEM-SS T cells. The Tre-specific LoxLTR target site was detected by
PCR analysis. M, 1 kb NEB marker; T, 1:10 diluted total input samples (positive PCR control); P, pull-down of Tre-recombinase using specific antibodies
(a-Tre) or non-specific IgG. The LoxLTR-specific PCR products are shown.
doi:10.1371/journal.pone.0031576.g005
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unrecombined PCR product in HTLMNT-treated cells, both at
the episomal and chromosomal level. Moreover, the HTLMNT
protein was more soluble than the other CPTR tested (data not
shown). Hence, we next wanted to determine the potential of the
HTLMNT protein to excise full-length HIV-1 genomes from their
chromosomal integration sites. First, we generated HeLa and
CEM-SS cells that were infected with pseudotyped HIV-1 and
therefore contain integrated full-length HIV-1 proviral DNA
(Figure 6A). We then tested the ability of transduced HTLMNT to
excise the provirus from the genome. Tre-mediated recombination
of the respective LoxLTR sequences leaves a single LTR at the
respective chromosomal integration site and produces a circular 1-
LTR recombination product, which is ultimately degraded by
cellular nucleases. Indeed, by using HIV-1 gene-specific oligonu-
cleotide pairs (denoted P3 and P4 in Figure 6A), the excised HIV-1
genome was specifically detected by PCR, thereby indicating Tre-
mediated recombination. Furthermore, after exposure of these
HIV-1 infected cells to increasing amounts of HTLMNT protein,
recombination of LoxLTR occurred in a dose-dependent manner
and was even observed at the lowest concentration tested, both in
HeLa cells (Figure 6B) and CEM-SS T cells (Figure 6C).
Moreover, DNA sequencing of the respective PCR products
resulted in the detection of the expected HIV-1-derived sequences,
including the Tre-specific LoxLTR target site (data not shown).
We therefore conclude that CPTR are useful for the excision of
integrated HIV-1 proviral DNA from the genome of infected cells
and may therefore present important components of advanced
future antiretroviral therapies.
Discussion
In the past decade there has been tremendous progress in the
development of drug delivery techniques and the application of
PTD seems more accessible than ever, although this technique has
so far not been introduced into the clinic. The main advantage of
using these systems is their ability to deliver bioactive molecules,
including genes, siRNA, oligonucleotides, peptide nucleic acids
(PNA), proteins, peptides and liposomes into all types of cells in
vitro and, furthermore, into various organs in vivo [21,26,27]. Thus,
PTD’s intrinsic internalization properties have been exploited in
many new therapeutic applications [25] and may therefore play an
increasingly important role in future disease treatments [27]. In
fact, PTD fused proteins are already widely used for delivering
anticancer agents (reviewed in [44]). For example, the HIV-1 Tat
peptide fused to Bcl-xL and pyrimidine dimer glycolase proteins
was used in ischemic brain injury and skin cancer treatment,
respectively [31,45,46]. Moreover, the PTD derived from the
HSV VP22 protein was exploited for the delivery of the GAT4
transcription factor to combat myocardial injury [47].
Technically, the tagging of a PTD to the cargo protein can be
easily achieved via molecular cloning and subsequent expression of
the respective fusion protein [45,47,48]. In particular, a novel
PTD or translocation motif (TLM with high transfer efficiency)
has been discovered in the hepatitis B virus PreS2 protein [38,49].
Its low immunogenicity, high spreading capacity, and its defined
structure-function relationship has made this PTD an efficient and
valuable tool for biomolecule delivery [32,38,50].
Novel experimental therapies for the treatment of HIV/AIDS
focus on the eradication of HIV-1 in infected individuals, thereby
potentially providing a cure for this chronic and life-threatening
disease (reviewed in [51,52]). In this respect various RNA-based
technologies are currently investigated, including application of
RNA aptamers, siRNA and shRNA, TAR decoys and ribozymes
[53–57]. Clearly, these approaches efficiently suppressed virus
replication and reduced viral loads for extended periods of time,
but so far failed in virus eradication. In that respect, mainly two
different antiviral strategies are currently investigated. The
genomic disruption of the CCR5 gene, encoding the essential
cellular coreceptor of CCR5-tropic (R5) viruses, by expressing
engineered zinc finger nucleases (ZFN), has been shown to result
in impaired surface expression of CCR5 and, consequently, in
resistance to de novo infection by CCR5-tropic HIV-1 [58,59].
Another strategy, which is independent of the tropism of the virus,
targets already HIV infected cells by removing the integrated
proviral DNA from the host cell. This approach is based on the
cellular expression of gene sequences encoding a tailored LTR-
specific recombinase, which was obtained in vitro by directed
molecular evolution technology and recognizes a primary HIV-1
Figure 6. Excision of integrated HIV-1 proviral genomes. (A)
Depiction of the integrated proviral DNA and the products originating
from Tre-mediated LoxLTR recombination. P1 and P2 denote PCR
primer binding sites used for the detection of the excised circular
recombination product. HIV-1 infected HeLa (B) and CEM-SS (C) cells
were exposed to the indicated concentrations of recombinant HTLMNT
protein. At 48 h post protein transduction genomic DNA was isolated
and subjected to PCR. The recombination product is represented by the
amplification of a 1.1 kB DNA fragment. NC, negative control in which
HTLMNT was omitted; PC, positive control in which Tre was
coexpressed from the p3Tre expression vector; M, DNA size markers.
doi:10.1371/journal.pone.0031576.g006
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peuticapproachmaybe accomplishedbydirectgene transferofTre
encoding sequences into potential HIV-1 host cells (or respective
progenitor cells). However, this gene transfer requires the use of
advanced vector systems, that are frequently derived from
pathogenic viruses [20,60,61]. Therefore, the required vector-
mediated gene transfer may by itself pose some significant health
risks [60,62,63]. It would be therefore advantageous if antivirals,
such as biologically active Tre-recombinase (or engineered ZFN),
could be directly and efficiently delivered into host cells.
Such a strategy could be particularly conceived in case of T cell-
based therapies in which the patient’s PBMC can be easily harvested
by apheresis [64]. The purified T lymphocytes would then be
transduced in vitro, potentially expanded and reinfused into the
respective donor. By transducing these cells directly with cell
permeable antivirals, such as for example CPTR, gene transfer
procedures could be complemented or entirely avoided, an aspect
that may significantly improve the safety of such advanced therapies.
The data raised in the present study suggest that CPTR, and in
particular the HTLMNT variant of recombinant Tre-recombi-
nase, is useful in such or a comparable therapy procedure. As
shown, all the tested proteins purified from E.coli to near
homogeneity using two chromatography techniques, were not
toxic in HeLa cells (at a maximum concentration of 1 mM) and
were efficiently internalized by cells when added to the respective
cultures. Importantly, all tested recombinant Tre proteins were
able to excise LoxLTR flanked regions of HIV-1, both on
transiently transfected reporter plasmids as well as in the genomic
context in stable reporter cell lines. Although the HT protein,
which lacks any PTD and NLS, was able to cross the cellular
plasma membrane, it was clearly less active as compared to PTD
tagged proteins (HTatNT and HTLMNT). The HTLMNT
protein displayed high solubility, stability and apparently the
highest efficiency of all Tre variants tested. This might reflect the
fact that in contrast to the HIV-1 Tat-derived peptide, HBV PreS2
TLM-dependent translocation occurs independent from endocytic
processes [39,65]. Rather, TLM-fused proteins translocate directly
across the cellular membrane into the cytoplasm [39], a process
that might help to preserve a higher enzymatic activity and a
longer protein half-life. Further experiments are in progress to
optimize the technology and to investigate the protein kinetics and
activity in different cell lines and primary cells. However, this first
report and data of cell permeable recombinant Tre activity
indicates the potential of these proteins for use as a nano-surgical
tool to potentially reverse HIV-1 infection and thereby curing
infected cells. Thus, the application of recombinant PTD-Tre
might contribute to future antiretroviral therapies of the post
HAART era.
Materials and Methods
Generation of cell permeable Tre-recombinases
The XL-gold strain of E. coli (Agilent Technologies) was used for
cloning, DNA sequencing and propagation of plasmids. All of the
Tre-recombinase proteins were amino-terminal hexa histidine
tagged (H) with a thrombin cleavage site separating the His-tag
and the Tre-recombinase. The Tre-recombinase (T), without
nuclear localization signal (NLS) and PTD is designated as HT
and with NLS is designated HNT. The HT and HNT constructs
were inserted in the pET28b vector at NdeIa n dXhoI sites using the
following primers; forward primer for HT; 59-CGCATATGTC-
CAACCTGCTGACC-39, forward primer for HNT; 59-CGCA-
TATGGTGCCCAAGAAGAAGCGGA-39 and reverse primer for
both HT and HNT; 59-CGCTCGAGTCAATCGCCATCTTC-
CAGCAG-39. The sequences in italics correspond to NdeI and XhoI
sites in the forward and reverse primers, respectively. The HIV-1
Tat PTD and HBV PreS2 TLM -tagged Tre-recombinase proteins
were designated HTatNT and HTLMNT, respectively. The
HTatNT and HTLMNT constructs were propagated in the
pTrcHisC vector as follows. First, the order of the HindIII and
XhoI restriction sites in the parental pTrcHisC vector was changed
byinsertion ofanoligonucleotidecontainingtheTat-PTDsequence
using primers (forward primer; 59-GATCTCTGGCCGTAAAA
AGCGCCGTCAGCGCCGCCGT AAGCTTGGTGCTTCT-
CATCTCGAGT-39; and reverse primer 59- AGCTACTC GAG-
ATGAGAAGCACCAAGCTTACGGCGGCGCTGACGGCG-
CTTTTTACGGCCAGA-39), or without the Tat-PTD-sequence
(forward primer; 59- GATCTCTAAGC TTGGTGCTTCT-
CATCTCGAGT-39 and reverse primer; 59-AGCTACTCGA
GATGAGAAGCACCAAGCTTAGA-39). The Tre sequence was
subsequently inserted into the HindIII and XhoI vector sites. The
construct without Tat-PTD was used to generate HTLMNT by
insertion of a TLM-oligonucleotide into the HindIII site (forward
primer 59-AGCTACCCTTATCGTCAATCTTTTCGCGAAT-
CGGCGATCCTG-39; reverse primer 59-AGCTCAGGAT-
CGCCGATTCGCGAAAAGATTGACGATAAGGGT-39). Tre
tagged with inverted TLM sequences was designated as
HTLMIRNT and was also generated in two steps. First, the
TLMIR sequence, encoding the amino acid sequence NH2-
PDGIRSFISSLP-SGS-PLSSIFSRIGDP-COOH, was PCR ampli-
fied from the vector pAS2-TLM2X [39] using the forward primer
59-CGACATATGCCTGATG GCATCCGATCG-39 and the re-
verse primer 59-CGAGGATCCAGGGTCCCCAATCCT CGA-
GAA-39 and inserted into the NdeIa n dBamHI sites of pET28b.
Next, the Tre- recombinase gene with NLS was fused at BamHIa n d
HindIII sites using the forward primer 59-CGGGATCCA-
TGGTGCCCAAGAAGAAG-39 and the reverse primer 59-
CGCAAGCTTTCAGTCGCCGTCCTCCAGCAGTCT-39. All
constructs were confirmed by DNA sequencing using T7 sense
and antisense primers.
The E. coli strain Rosetta (Novagen) was employed for protein
expression. The respective genes were cloned in different vectors
for expression in the various host systems depending upon their
expression and solubility.
Over expression of Tre-recombinases
For over expression the HT, HNT and HTLMIRNT encoding
plasmids were transformed into E.coli Rosetta cells (Novagen),
plated on Luria-Bertini (LB)-kan dishes (50 mg/ml kanamycin) and
incubated at 37uC for 12 h. A single colony was used for
inoculation of 50 ml of LB-medium containing 50 mg/ml
kanamycin and grown for 12 h at 37uC (pre-inoculum). This
pre-inoculum (4%) was then used to inoculate 500 ml of terrific
broth (TB) containing 50 mg/ml kanamycin (450 ml TB medium
+50 ml of 0.17 M KH2PO4 and 0.72 M K2HPO4) and cultured at
37uC until an O.D.600 of 0.6 was reached. Tre-recombinase gene
expression was induced by addition of 0.5 mM of IPTG for a
period of 5 h at 30uC. Over expression of HTatNT and
HLTMNT was carried out using the same protocol, except for
using ampicillin selection (100 mg/ml) instead of kanamycin
selection. The cells were pelleted by centrifugation at 5.0006 g
for 10 min at 4uC and the cell pellets were stored at 280uC until
further use.
Purification of Tre-recombinase
Purification was carried out as previously described [28] with
slight modifications. Briefly, the cells from an induced culture were
harvested by centrifugation, resuspended in buffer 1 (50 mM Tris-
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and 0.1% Tween 20) in the presence of ‘‘complete EDTA-free
protease inhibitor cocktail’’ (Roche), and lysed by sonication. To
the total lysate ice cold 1 M L-tartaric acid was added slowly and
incubated for 5 min on ice. Insoluble debris was removed by
centrifugation and subsequently the cleared lysate was filtered
through 0.22 mm filter. The filtrate was directly loaded on to a
2 ml Ni-NTA beads column, pre-equilibrated with 20 mM Tris-
HCl (pH 8.0) containing 300 mM NaCl. The column was washed
with 100 ml of buffer 2 (20 mM Tris-HCl pH 8.0, 700 mM NaCl,
5% Glycerol, 0.1% Tween 20 and 20 mM Imidazole). Subse-
quently, the protein was eluted from the column in 5 ml of buffer 3
(20 mM Tris-HCl pH 8.0, 700 mM NaCl, 5% Glycerol, 5 mM b-
mercaptoethanol and 250 mM Imidazole). The 5 ml fraction was
filtered through 0.22 mm filter and directly loaded on S200
superdex column which was pre-equilibrated with buffer 4
(20 mM HEPES pH 7.4, 500 mM NaCl and 2 mM DTT) on
A ¨KTA purifier (GE Healthcare Life Sciences). The proteins were
eluted as 1 ml fractions at 1 ml/min flow rate and purity of the
protein in peak fractions was analyzed by 12% SDS-PAGE.
Specificity of the purified proteins was confirmed by Western
blotting using Tre-recombinase polyclonal antibodies.
Cell culture and plasmids
HeLa (ATCC Cat# CCL-2) were maintained in Dulbecco’s
modified Eagle medium (DMEM) supplemented with 10% (v/v)
fetal bovine serum (FBS), L-glutamine (2 mM), penicillin and
streptomycin. Stable pSVLoxLTR HeLa cell lines were main-
tained in complete DMEM media with 3 mg/ml puromycin.
CEM-SS cells (NIH AIDS Res. and Ref. Reagent Program Cat#
776) were cultivated in RPMI-1640 medium supplemented with
10% (v/v) FBS, L-glutamine (2 mM), penicillin and streptomycin.
Transient transfections were carried out using TransIT (Mirus,
USA) according to the instructions of the manufacturer. Plasmids
pSVLoxLTR and p3Tre were used for the transient transfection
recombination assays [16].
Analysis of cellular toxicity
Cell viability was analyzed by measuring cellular metabolic
activity using the alamarBlue redox indicator (Serotec), according
to the manufacturer’s protocol.
Protein transduction of mammalian cells
Protein transduction was performed as reported previously [28]
with slight modifications. The cells were seeded and grown
overnight prior to transduction. The following day, the cell
cultures were washed and incubated in serum free medium
(optiMEM; Gibco) for 2 h at 37uC. The cells were then treated
with recombinant Tre-recombinase proteins (1 mM) for 5 h in
serum free medium on a rocker platform at 37uC, which was
placed in the incubator. Subsequently, serum free media was
replaced with complete growth media, containing penicillin and
streptomycin, and further incubated for 48 h.
Immunofluorescence analyses
HeLa cells were seeded onto 15 mm glass cover slips in 22 mm
diameter dishes at a density of 1610
5 per well and grown
overnight at 37uC. Protein transduction was carried out as
described above. Five hours of post transduction the cells were
washed three times with PBS, followed by washing with 0.5 mg/
ml heparin in PBS (three times for 5 minutes each). For
microscopic analysis, cells were fixed with 3% paraformaldehyde
(PFA) for 20 min and then washed with 50 mM NH4Cl/PBS. The
cells were permeabilized with 0.1% Triton X-100/PBS for 5 min
and blocked with 0.5% BSA/PBS for 30 min at ambient
temperature. Proteins were immunolabelled in 0.5% BSA/PBS
using the Tre -recombinase polyclonal primary antibodies (1:100),
followed by FITC coupled secondary antibodies (Cy2; Molecular
Probes Invitrogen). Nuclear DNA was visualized by Draq5 (Enzo
Life Sciences). Samples were analyzed on a Axiovert 200 M
microscope equipped with an LSM 510 META confocal laser
scanning unit (Carl Zeiss) using a Plan-Apochromatic 636 oil
immersion objective lens with a 1.4 numeric aperture. Image
acquisition and processing was performed by using the Zeiss LSM
imaging software.
PCR analysis of Tre-recombination activity
In transient transfection experiments Tre recombination of
LoxLTR sites was detected by PCR [16]. Briefly, 8–10610
6 HeLa
were transiently transfected with 20 mg of the pSVLoxLTR
reporter construct [16] using TransIT-LT1 (Mirus) according to
the manufacturer’s instructions. The following day, 2610
5 of the
transfected cells were seeded in 35 mm diameter plates. In one
culture, the expression plasmid p3Tre (1 mg) was co-transfected for
positive control. The following day, protein transduction was
carried out. At 48 hours post transduction, the cells were
trypsinized, washed and genomic DNA was isolated using the
Blood mini kit (Qiagen). For detection of the recombination
product PCR was performed using 1 mg of genomic DNA as
template and the P1 (59-GCCTCGGCCTAGGAACAGT-39) and
P2 (59-CCGCCACATATCCTGATCTT-39) primer pairs. The
amplification profile involved 30 cycles of denaturation at 94uC for
30 seconds, primer annealing at 52uC for 30 seconds and
extension at 72uC for 2 min. Final extension was at 72uC for
10 minutes. PCR was performed in a total volume of 50 mlo f
16of 5-prime-PCR-mix (Thermo Scientific).
For internal control, expression plasmid-derived unrecombined
amp sequences were detected as before using following oligonu-
cleotide primer pairs: forward 59-ATGAGTATTCAA-
CATTTCCG-39 and reverse 59-TTACCAATGCTTAAT-
CAGTGAGG-39.
Detection of Tre recombination in stable pSVloxLTR HeLa
reporter cells [16] was performed as follows. Protein transduction
was carried out as before in a 10 cm diameter culture dish at a
density of 1.2610
6 cells. After 48 h of protein transduction, whole
genomic DNA was isolated from the transduced cells and PCR
was performed using P1 and P2 specific primers to detect the
recombination activity as described above. The p3Tre plasmid
was transiently transfected as a positive control.
Half-life determination of HTatNT and HTLMNT
HeLa cells (2610
5) were transduced with CPTR and their half-
life was tested according to Peitz and coworkers [28]. After protein
transduction, loosely bound proteins were removed by three
washes with PBS followed by three washing steps (5 min each)
with 0.5 mg per ml heparin in PBS. The cellular lysates were
prepared for the indicated periods of time and the protein level in
the lysates was detected by immunoblotting with anti-Tre
polyclonal antibodies.
Chromatin immunoprecipitation (ChIP) assay
ChIP assays were performed to determine the binding of CPTR
to the specific LoxLTR sequence in living cells. HIV-1 infected
CEM-SS cells were seeded with 2610
6 cells per well into 32 mm
diameter culture dishes. HTLMNT and HTatNT proteins were
transduced as described before and, at 3 hours post transduction,
ChIP assay was performed using Tre-specific rabbit polyclonal
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according to manufacturer’s protocol (Thermo Scientific, Ger-
many). After pull-down of specific DNA, PCR was performed
using the LoxLTR-specific primers P3 (59 TACTTCCCT-
GATTGGCAGAACTACACACC 39) and P4 (59 TCA AGA
ACT GCT GAC ATC GAG C 39). PCR products were
subsequently visualized by agarose gel electrophoresis. The
sequence was also confirmed by DNA sequencing.
Excision of the full-length HIV-1 viral genome
HeLa and CEM-SS cell cultures were infected with HIV-1
pseudotypes, in which env sequences were deleted and the nef
coding region was substituted by the blasticidin resistance gene, as
described in detail previously [16]. Recombination activity of
HTLMNT was determined as follows: 2610
5 infected HeLa cells
or 2610
6 infected CEM-SS cells were seeded into 35 mm plates
and grown overnight. The following day protein transduction was
carried out as before and at 48 h post transduction whole genomic
DNA was isolated for detection of the excised circular proviral
DNA product by PCR using following primers: P5 forward primer
59GCTGCCCTCTGGTTATGTGTG and P6 backward primer
59 CTTAATACCGACGCTCTCGCAC.
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